Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Cardiovascular Therapeutics
|
November 27, 2010
Myocardial reverse remodeling
Jennifer L Hellawell, Kenneth B Margulies
Expert Opinion on Drug Metabolism & Toxicology
|
September 11, 2014
Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension
Jennifer L Hellawell, Sanjeeb Bhattacharya, Harrison W Farber
The American Journal of Cardiology
|
March 24, 2016
Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States
Martin S Maron, Jennifer L Hellawell, Jaime C Lucove, et al.
Clinical Pharmacology in Drug Development
|
June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers
Jonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Circulation. Heart Failure
|
February 27, 2016
Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial
Iacopo Olivotto, Jennifer L Hellawell, Ramin Farzaneh-Far, et al.
Journal of Cardiovascular Electrophysiology
|
October 16, 2010
Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance
James E Ip, Jim W Cheung, David Park, et al.
Journal of Medicinal Chemistry
|
April 29, 2009
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells
Matthew D Hall, Noeris K Salam, Jennifer L Hellawell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Cardiovascular Therapeutics
|
November 27, 2010
Myocardial reverse remodeling
Jennifer L Hellawell, Kenneth B Margulies
Expert Opinion on Drug Metabolism & Toxicology
|
September 11, 2014
Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension
Jennifer L Hellawell, Sanjeeb Bhattacharya, Harrison W Farber
The American Journal of Cardiology
|
March 24, 2016
Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States
Martin S Maron, Jennifer L Hellawell, Jaime C Lucove, et al.
Clinical Pharmacology in Drug Development
|
June 8, 2019
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers
Jonathan C Fox, Jennifer L Hellawell, Satish Rao, et al.
Circulation. Heart Failure
|
February 27, 2016
Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial
Iacopo Olivotto, Jennifer L Hellawell, Ramin Farzaneh-Far, et al.
Journal of Cardiovascular Electrophysiology
|
October 16, 2010
Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance
James E Ip, Jim W Cheung, David Park, et al.
Journal of Medicinal Chemistry
|
April 29, 2009
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells
Matthew D Hall, Noeris K Salam, Jennifer L Hellawell, et al.
Page
of 1